pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. .

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8)

Vaccination 105

Vaccination Vaccine Immune Response Scientist 105

STAT News

OCTOBER 19, 2022

… Moderna disclosed that its Covid-19 vaccine booster targeting the BA.1 1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months , Reuters notes. Omicron-tailored 5 targeted vaccine later this year.

Immune Response 98

Immune Response Scientist Vaccination Vaccine 98

Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 104

Vaccination Vaccine Research Immune Response 104

Sciensano

JULY 5, 2023

Vaccin COVID-19 Event type: symposium Audience: general public health professionals journalist PhD students policy makers scientists Description: Sciensano is pleased to invite you to its BelCoVac symposium, which will focus on studies on the COVID vaccine in Belgium.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

The Pharma Data

SEPTEMBER 14, 2020

Illustration of antibodies attacking the coronavirus. A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. What are monoclonal antibodies?

Antibody 52

Antibody Trials Immune Response Vaccination 52

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community. References.

Scientist 52

Scientist Immune Response Antibody Development 52

The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. More recently, the university has released news of its collaboration with Thermo Fisher Scientific as it looks to discover an immune Covid-19 response pre- and post-vaccination.

Antibody 52

Antibody Vaccination Vaccine Containment 52

pharmaphorum

SEPTEMBER 8, 2022

A malaria vaccine developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab has been hailed as a possible game-changer in the fight against the deadly parasitic infection. g) dose of Novavax’ Matrix-M adjuvant, used to boost the immune response to the R21 antigen. g) or high (50 ?g)

Vaccination 70

Vaccination Vaccine Immune Response Antibody 70

The Pharma Data

NOVEMBER 10, 2021

Next generation vaccines for COVID-19 should aim to induce an immune response against ‘replication proteins’, essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. ” Discovering the T cell response to replication proteins.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

Drug Discovery World

JANUARY 12, 2024

The top stories: Excitement over new antibiotics that can kill drug-resistant bacteria A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

The Pharma Data

AUGUST 9, 2021

Research by Lancaster University scientists to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus.

Vaccination 52

Vaccination Vaccine Immune Response Scientist 52

XTalks

JANUARY 11, 2023

It also seems to be very adept at evading the immune response owing to a plethora of mutations that makes it immune evasive. “It The new subvariant has also been dubbed “Kraken” by some scientists. on the horizon as scientists say the virus appears to be rapidly evolving , mutating faster than most viruses.

Scientist 98

Scientist Vaccination Vaccine Genetics 98

pharmaphorum

SEPTEMBER 29, 2020

Inovio Pharma’s plan to start pivotal testing of its COVID-19 vaccine has been delayed by FDA requests for more information, sending its shares into a swift decline. Inovio’s vaccine takes the form of a DNA plasmid coding for the full length of the spike or ‘s’ glycoprotein antigen of SARS-CoV-2, the vaccine that causes COVID-19.

Vaccination 52

Vaccination Vaccine Trials DNA 52

The Pharma Data

OCTOBER 18, 2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.

Vaccination 40

Vaccination Vaccine Immune Response Antibody 40

The Pharma Data

SEPTEMBER 30, 2021

An expert review by a world group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the overall population aren’t appropriate at this stage within the pandemic.

Vaccination 52

Vaccination Vaccine Antibody Immune Response 52

Drug Discovery World

JULY 26, 2022

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The first half of the lecture, titled ‘mRNA Cancer Vaccines’ will be delivered by U?ur The lecture will be delivered in two halves by U?ur

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

pharmaphorum

DECEMBER 11, 2020

Sanofi and GlaxoSmithKline have said their COVID-19 vaccine has hit a snag in clinical development, prompting analysts to note this could delay delivery of potentially more than a billion shots globally by up to nine months. AZ to combine vaccine with Russian rival.

Immune Response 72

Immune Response Trials Vaccination Vaccine 72

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

pharmaphorum

FEBRUARY 18, 2021

The South African coronavirus variant may cut the effectiveness of Pfizer/BioNTech’s vaccine by around two thirds, according to a laboratory study. Mutations may alter neutralisation by affecting spike function rather than antigen response and its also unclear from this study how the T-cell response is affected.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. White fat, in contrast, can build up and cause obesity.

Vaccination 53

Vaccination Vaccine Research Trials 53

Pharmaceutical Technology

JULY 22, 2022

In addition, immunity against the infection is found to wane for both previously infected individuals and the vaccinated. Muge Cevik, a clinical scientist, shared an article around the mystery of viral hepatitis cases in children. Peter Hotez’s tweet on PAI Life Sciences’ phase 1 trial of its snail fever vaccine.

Vaccination 130

Vaccination Vaccine Life Science Immune Response 130

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. Singapore biotechnology company. population.

Immune Response 52

Immune Response Protein Medicine Genetics 52

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. The institute also led and funded early-stage clinical research into the vaccine candidate.

Vaccination 103

Vaccination Vaccine Development Research 103

Find Me Cure

APRIL 23, 2020

The far more boring truth is that scientists are not magicians or prophets and estimations cannot always be precise. Firstly, even though scientists are busy developing a vaccine, one is not expected earlier than 2021. Thus, herd immunity wouldn’t work in this scenario. Myth 3: Healthy young people don’t get sick.

Immune Response 117

Immune Response Antibody Scientist Development 117

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. These epitopes could then be used in a vaccine to train T cells, providing protective immunity.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. A Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether a type of antibody called IgE could be used to treat cancer.

Development 64

Development Research Drugs Antibody 64

The Pharma Data

JANUARY 5, 2021

Food and Drug Administration said Monday that any American who gets the Moderna or Pfizer coronavirus vaccines must get two full doses, despite international debate on possible ways to stretch vaccine supply. vaccine effort just as the public is starting to trust the program, Dr. Anthony Fauci told The New York Times.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

MARCH 8, 2022

The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines. While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly.

Immune Response 52

Immune Response RNA Protein Genetics 52

The Pharma Data

JANUARY 22, 2021

Next on the agenda: speeding up the nation’s vaccine rollout. To help do so, he’s directed the Federal Emergency Management Agency to begin constructing federally supported community vaccination centers, with the goal of having 100 centers in operation within the next month, The New York Times reported.

Vaccination 52

Vaccination Vaccine Antibody Reagent 52

The Pharma Data

JANUARY 3, 2021

Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”. Dr Thais Moreira, the lead scientist and coordinator of the clinical trial, stated: “We are delighted to receive positive feedback from patients treated in the clinical trial. . NEW YORK and LONDON, Jan.

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

The Pharma Data

MARCH 16, 2021

Accurate detection and differentiation of SARS-CoV-2 mutations can help assess the spread of circulating variants and monitor their potential impact on therapeutics, vaccines and public health interventions. 1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy.

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

Roots Analysis

FEBRUARY 23, 2024

Imagine a world where scientists work together to create special “soldiers” in our bodies called antibodies. Sometimes, scientists ask for help from experts who are really good at finding and designing these antibodies. What are the steps involved in an antibody discovery project?

Antibody 40

Antibody Research Marketing Scientist 40